Regenxbio (RGNX) Stock Price
Regenxbio Price
Revenue has compounded at 32.0% per year over the past 12 years to 170.44 M USD. Regenxbio's net margin stands at -113.8%, down from 27.2% several years earlier. Analysts set a median price target of 18.00 USD, implying 151.0% above the current price. Of 18 analysts, 15 rate the stock a buy — an overall Buy consensus.
Regenxbio stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Regenxbio business model & stock analysis
Frequently asked questions about Regenxbio
The business model of Regenxbio Inc is focused on developing and commercializing gene therapy treatments for various genetic diseases. Regenxbio utilizes its proprietary adeno-associated virus (AAV) gene delivery platform, which enables targeted and precise gene therapy delivery to specific cells in the body. This versatile platform allows Regenxbio to address a wide range of genetic disorders, including neurodegenerative diseases, metabolic disorders, and ophthalmic diseases. By leveraging their expertise in gene therapy and collaborating with partners, Regenxbio aims to bring effective and innovative treatments to patients with unmet medical needs.
Regenxbio Inc is primarily active in the biotechnology industry.
The main competitors of Regenxbio Inc in the market include other gene therapy companies such as bluebird bio, Sangamo Therapeutics, uniQure, and Spark Therapeutics.
Regenxbio Inc. is a biotechnology company focused on the development and commercialization of gene therapy treatments. Founded in 2008, Regenxbio has grown into a leading player in the field of gene therapy, with a strong emphasis on adeno-associated virus (AAV) vector technology. The company has developed a proprietary NAV Technology Platform, which enables the precise and targeted delivery of therapeutic genes to specific cells in the body. Regenxbio has made significant strides in advancing gene therapy treatments for various genetic disorders, including ophthalmic, metabolic, and neurodegenerative diseases. As an innovative and pioneering company, Regenxbio is committed to revolutionizing the future of gene therapies.
Regenxbio Inc has achieved several significant milestones in its history. One notable milestone is the successful completion of a Phase I clinical trial for its lead product candidate, RGX-314. This novel gene therapy aims to treat wet age-related macular degeneration (AMD). Additionally, Regenxbio has entered into partnerships with renowned pharmaceutical companies, including Novartis and Audentes Therapeutics, to further expand its gene therapy platform. The company has also garnered regulatory approvals for its gene therapy products, including FDA breakthrough therapy designation for RGX-314. These achievements highlight Regenxbio's commitment to developing innovative gene therapies for various genetic disorders, including eye diseases.
Regenxbio Inc is primarily present in the United States.
Regenxbio Inc is a renowned biotechnology company specializing in the development of life-changing gene therapies for patients suffering from severe diseases. The company's core values revolve around innovation, scientific excellence, and patient-centric focus. Regenxbio Inc is dedicated to improving the lives of individuals by harnessing the power of gene therapy to address unmet medical needs. With a commitment to integrity, collaboration, and transparency, Regenxbio Inc strives to bring groundbreaking treatments to patients, build strong partnerships, and continuously push the boundaries of scientific discovery. Their corporate philosophy embodies a relentless pursuit of transformative therapies to revolutionize healthcare and provide hope for those in need.
Analysts currently set an average price target of 20.60 USD for the Regenxbio stock (median: 18.00 USD), implying +187.3 % versus the latest price. The consensus is based on 18 analyst ratings.
18 analysts currently rate the Regenxbio stock: 15 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Regenxbio to generate revenue of 161.00 M USD and earnings per share of -3.35 USD.
Converted at the current exchange rate, the Regenxbio share trades at 6.38 EUR (7.17 USD).
The Regenxbio share (RGNX) is listed on 4 stock exchanges, including: NASDAQ (RGNX), Frankfurt (RB0.F), München (RB0.MU), Düsseldorf (RB0.DU).
Regenxbio Inc is a biopharmaceutical company focused on the development of gene therapies for rare genetic diseases. The company's business model is based on the discovery, development, and commercialization of innovative gene therapies to improve the lives of patients worldwide. Regenxbio was founded in 2009 and is headquartered in Rockville, Maryland (USA). As a pioneer in the field of gene therapy, the company has developed an extensive platform based on AAV vector technology. This platform allows Regenxbio to develop customized gene therapies and create new treatment options for patients with rare diseases. Regenxbio's research and development focuses on the identification and characterization of AAV vectors, each capable of transporting and expressing specific genes. Regenxbio has developed a wide range of AAV vectors tailored to the needs of patients with different conditions. The company has partnerships with numerous pharmaceutical and biotech companies such as Novartis, Alexion Pharmaceuticals, and Pfizer. These partnerships focus on the development of gene therapy solutions for various diseases such as cystic fibrosis, hemophilia, and Fabry disease. Regenxbio also has its own pipeline of gene therapy products in various stages of clinical development. Some of the products developed by Regenxbio include: - RGX-314: A gene therapy for the treatment of wet age-related macular degeneration (AMD). This therapy is based on the use of AAV8 vectors to transport the gene for the anti-VEGF antibody into the eye. - RGX-121: A gene therapy for the treatment of mucopolysaccharidosis type II (MPS II). This therapy is based on the use of AAV9 vectors to transport the gene for the enzyme iduronate-2-sulfatase (IDS) into the brain. - RGX-111: A gene therapy for the treatment of mucopolysaccharidosis type I (MPS I). This therapy is based on the use of AAV9 vectors to transport the gene for the enzyme alpha-L-iduronidase (IDUA) into the brain. - RGX-501: A gene therapy for the treatment of hemophilia A. This therapy is based on the use of AAV8 vectors to transport the gene for factor VIII into the liver. Regenxbio is on its way to becoming one of the leading companies in the gene therapy industry. The customized platform for gene therapy development, close collaboration with partners, and the company's own pipeline of gene therapy products should bring growth and success to the company in the future.
The expected revenue of Regenxbio is 161.00 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Regenxbio is -173.47 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Regenxbio is currently -2.14. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Regenxbio stock.
The price-to-sales ratio (P/S) of Regenxbio is currently 2.30. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Regenxbio stock.
The Eulerpool Quality Score for Regenxbio is 3/10.
The ISIN of Regenxbio is US75901B1070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Regenxbio is A140E0. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Regenxbio is RGNX. The ticker symbol is used to trade Regenxbio shares on the stock exchange.
Regenxbio stock
Regenxbio Peer Group
Regenxbio Ticker
Regenxbio FIGI
All fundamentals and in-depth analysis of Regenxbio
Our stock analysis for Regenxbio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regenxbio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.